Antibody–Drug Conjugate to Treat Meningiomas

Volume: 14, Issue: 5, Pages: 427 - 427
Published: May 2, 2021
Abstract
Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) to target and treat meningiomas. The meningioma targeting, circulation stability, toxicity, and anti-tumor...
Paper Details
Title
Antibody–Drug Conjugate to Treat Meningiomas
Published Date
May 2, 2021
Volume
14
Issue
5
Pages
427 - 427
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.